Filed by NewAmsterdam Pharma Company B.V.
Pursuant to Rule 425 under the Securities Act of 1933,
as amended, and deemed filed pursuant to Rule 14a-12
of the Securities Exchange Act of 1934, as amended
Subject Company: Frazier Lifesciences Acquisition Corporation
Commission File No. 001-39765
The following press release was made available by NewAmsterdam Pharma on August 29, 2022:
NewAmsterdam Pharma Showcases Leadership in Cardiometabolic Disease Treatment in Multiple Presentations at ESC Congress 2022
— Emerging data reinforce combination lipid-lowering therapy as first-line strategy for very high-risk patients, supporting the development of obicetrapib as adjunct to high-intensity statins —
Naarden, the Netherlands and Miami, USA; August 29, 2022 – NewAmsterdam Pharma (NewAmsterdam Pharma), a clinical-stage company focused on the research and development of transformative oral therapies for metabolic diseases, today announced emerging data adding to the growing body of clinical evidence supporting a shift in the treatment paradigm towards prioritizing a combination approach as first-line therapy for very high-risk atherosclerotic cardiovascular disease (ASCVD) patients. These data were presented in a plenary session at the ESC Congress 2022, taking place August 26-29, 2022 in Barcelona, Spain and virtually, by John Kastelein, M.D., Ph.D., F.E.S.C., chief scientific officer at NewAmsterdam Pharma.
“The causality of low density lipoprotein cholesterol (LDL-C) as the primary driver of cardiovascular disease is well-established and LDL lowering has become a cornerstone in the treatment of ASCVD patients,” said Dr. Kastelein. “Even so, there remains a wide gap between guideline-recommended LDL-C goals and what’s achieved in real-world practice, with many patients insufficiently addressed due to limitations of currently available therapies and market access hurdles. The need for a paradigm shift away from statin monotherapy in very high risk patients is evident and physicians are increasingly turning to intensive lipid-lowering as a first-line treatment strategy. Data presented at the ESC Congress 2022 suggest early use of combination approaches in very high risk patients, like the addition of obicetrapib, if approved, as an adjunct to maximally tolerated statin therapy, could serve as an important tool in the armamentarium of treating cardiologists, enabling them to more efficiently and pragmatically ensure that a higher proportion of patients reach their LDL-C goals.”
Dr. Kastelein’s plenary presentation discussed the role of elevated levels of LDL-C as the root cause of cardiovascular disease and the limitations of current standards of care, and introduced a simplified treatment algorithm for treating high-risk patients with combination therapy as an initial strategy. As part of his presentation, Dr. Kastelein also presented previously-disclosed results from the Phase 2b clinical trial, ROSE, in which robust LDL-C lowering was observed following treatment with obicetrapib as an adjunct to high-intensity statins.
NewAmsterdam Pharma is developing obicetrapib, a next-generation, oral, low-dose and once-daily cholesteryl ester transfer protein (CETP) inhibitor, for patients at very high risk for cardiovascular disease as an adjunct to maximally tolerated statin therapy, both as a monotherapy and in a fixed-dose combination with ezetimibe.
Obicetrapib is currently being evaluated in three Phase 3 clinical trials, BROADWAY (LDL-lowering capability in patients on maximum tolerated lipid-modifying therapies with established atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia (HeFH) with LDL-C ≥ 70 mg/dL), BROOKLYN (LDL-lowering capability in HeFH patients on maximum tolerated lipid-modifying therapies with LDL-C ≥ 70 mg/dL), and PREVAIL (CVOT in patients on maximum tolerated lipid-modifying therapies with atherosclerotic cardiovascular disease with LDL-C ≥ 70 mg/dL), as well as a Phase 2b clinical trial, ROSE2, which is examining obicetrapib as a fixed-dose combination therapy with obicetrapib 10 mg and ezetimibe 10 mg in patients on high-intensity statin therapy with LDL-C ≥ 70 mg/dL.
Also at the ESC Congress 2022, Dr. Kastelein presented a new post-hoc analysis from the Phase 2 TULIP trial, comparing the accuracy of three clinically implemented LDL-C equations. In European patients with dyslipidemia receiving a CETP inhibitor, data showed improved LDL-C accuracy using contemporary equations versus the Friedewald equation, with the greatest accuracy observed using the Martin/Hopkins equation. These data reinforce the known limitations of the Friedewald equation, as well as the importance of adopting new methods that can more accurately measure LDL-C, especially in patients with lower LDL-C levels, in order to enable physicians to make better informed treatment recommendations and ensure their patients are not deferring or withdrawing critical lipid-lowering therapy.
Dr. Kastelein also participated in sessions discussing how to manage patients with high LDL-C and guidelines and paradigm shifts in LDL-C management.
About NewAmsterdam Pharma
NewAmsterdam Pharma is a private clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where traditional therapies have not been sufficiently successful or well-tolerated. NewAmsterdam Pharma is investigating obicetrapib, a next-generation oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C-lowering therapy for high-risk cardiovascular disease (“CVD”) patients. Results from NewAmsterdam Pharma’s ROSE Phase 2b trial (presented at AHA Scientific Sessions in 2021) included observations that patients receiving obicetrapib 10 mg experienced a median reduction in LDL-C by 51% versus baseline in patients on statin therapy (vs. a 7% reduction in the placebo arm). Based in the Netherlands, NewAmsterdam Pharma was founded in 2019 by the venture capital firm Forbion and John Kastelein, Chief Scientific Officer of the NewAmsterdam Pharma, and closed a $196 million (€160 million) Series A financing in January 2021 led by Forbion, Morningside Ventures and Ascendant BioCapital. In June 2022, NewAmsterdam Pharma entered into an exclusive licensing agreement with the Menarini Group for the commercialization of obicetrapib in Europe, while retaining all rights to commercialize obicetrapib, if approved, in the rest of the world, as well as rights to develop certain forms of obicetrapib for other diseases such as Alzheimer’s disease. For more information, please visit: www.newamsterdampharma.com.
About Frazier Lifesciences Acquisition Corporation
Frazier Lifesciences Acquisition Corporation (“FLAC”) is blank check company incorporated as a Cayman Islands exempted company in October 2020 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. FLAC was formed to leverage the extensive experience and track record of its management team with the goal of financing a company that can both develop transformative therapies for patients in need and deliver significant returns to its investors. For more information, please visit: www.frazierlifesciencesacquisition.com.
About Frazier Healthcare Partners
Founded in 1991, Frazier Healthcare Partners is a leading provider of private equity capital to healthcare companies. With more than $8.1 billion total capital raised, Frazier has invested in more than 200 companies with transaction types ranging from buyouts of profitable healthcare companies to venture capital and company creation. Frazier has a philosophy of partnering with strong management teams while leveraging its internal operating resources and network to build exceptional companies. Frazier has offices in Seattle, Washington, and Menlo Park, California, and invests broadly across the U.S., Canada and Europe. For more information, please visit: www.frazierhealthcare.com.
Important Information About the Merger and Where to Find It
In connection with the previously announced business combination between NewAmsterdam Pharma and FLAC, NewAmsterdam Pharma Holding B.V. (the “Company”) has filed a registration statement on Form F-4 with the SEC that includes a prospectus with respect to the Company securities to be issued in connection with the business combination and a proxy statement with respect to the shareholder meeting of FLAC to vote on the business combination. FLAC, the Company and NewAmsterdam Pharma urge its investors,
shareholders and other interested persons to read the preliminary proxy statement/prospectus, as well as other documents filed with the SEC, because these documents will contain important information about FLAC, the Company, NewAmsterdam Pharma and the transaction. After the registration statement is declared effective, the definitive proxy statement/prospectus to be included in the registration statement will be mailed to shareholders of FLAC as of a record date to be established for voting on the proposed business combination. Once available, shareholders of FLAC will also be able to obtain a copy of the Form F-4, including the proxy statement/prospectus, and other documents filed with the SEC without charge, by directing a request to: Frazier Lifesciences Acquisition Corporation, Two Union Square, 601 Union St., Suite 3200, Seattle, WA 98101, Attn: Secretary. The preliminary and definitive proxy statement/prospectus to be included in the registration statement, once available, can also be obtained, without charge, at the SEC’s website at www.sec.gov.
Participants in the Solicitation
FLAC, the Company and NewAmsterdam Pharma and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from FLAC’s shareholders in connection with the proposed transaction. Information about the directors and executive officers of FLAC is set forth in FLAC’s annual report on Form 10-K filed with the SEC on March 25, 2022 and is available free of charge at the SEC’s website at www.sec.gov or by directing a request to: Frazier Lifesciences Acquisition Corporation, Two Union Square, 601 Union St., Suite 3200, Seattle, WA 98101, Attn: Secretary. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of FLAC’s shareholders in connection with the potential transaction are set forth in the registration statement containing the preliminary proxy statement/prospectus filed with the SEC. These documents can be obtained free of charge from the sources indicated above.
Non-Solicitation
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.
Forward-Looking Statements
Certain statements included in this document that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics and projections of market opportunity; expectations and timing related to the success, cost and timing of product development activities, including timing of initiation, completion and data readouts for clinical trials and the potential approval of NewAmsterdam Pharma’s product candidate; the size and growth potential of the markets for NewAmsterdam Pharma’s product candidate; the therapeutic and curative potential of NewAmsterdam Pharma’s product candidate; financing and other business milestones; potential benefits of the proposed transactions; and expectations relating to the proposed transactions, including the proceeds of the business combination and NewAmsterdam Pharma’s expected cash runway. These statements are based on various assumptions, whether or not identified in this document, and on the current expectations of NewAmsterdam Pharma’s, the Company’s and FLAC’s management and are not predictions of actual performance. These forward looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of NewAmsterdam Pharma, the Company and FLAC.
These forward looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; the inability of the parties to successfully or timely enter into definitive agreements with respect to the proposed transactions or consummate the proposed transactions, including the risk that any regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions (such as any SEC statements or enforcements or other actions relating to special purpose acquisition companies) that could adversely affect NewAmsterdam Pharma or the expected benefits of the proposed transactions, or the risk that the approval of the shareholders of FLAC, the Company or NewAmsterdam Pharma is not obtained; failure to realize the anticipated benefits of the proposed transactions; matters discovered by FLAC, the Company or NewAmsterdam Pharma as they complete their respective due diligence investigations of each other; risks relating to the uncertainty of the projected financial information with respect to NewAmsterdam Pharma and the Company; risks related to the approval of NewAmsterdam Pharma’s product candidate and the timing of expected regulatory and business milestones; ability to negotiate definitive contractual arrangements with potential customers; the impact of competitive product candidates; ability to obtain sufficient supply of materials; the impact of COVID 19; global economic and political conditions, including the Russia-Ukraine conflict; the effects of competition on NewAmsterdam Pharma’s future business; the amount of redemption requests made by FLAC’s public shareholders; and those factors discussed in documents FLAC has filed or will file with the SEC, including the other risks and uncertainties described in the “Risk Factors” section of FLAC’s registration statement on Form S-1, as amended (File No. 333-250858), the registration statement filed on Form F-4 in connection with the proposed transactions and other documents filed from time to time. Additional risks related to NewAmsterdam Pharma’s business include, but are not limited to: uncertainty regarding outcomes of NewAmsterdam Pharma’s ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidate; risks associated with NewAmsterdam Pharma’s efforts to commercialize a product candidate; NewAmsterdam Pharma’s ability to negotiate and enter into definitive agreements on favorable terms, if at all; the impact of competing product candidates on NewAmsterdam Pharma’s business; intellectual property related claims; NewAmsterdam Pharma’s ability to attract and retain qualified personnel; ability to continue to source the raw materials for its product candidate. If any of these risks materialize or FLAC’s, the Company’s or NewAmsterdam Pharma’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither FLAC, the Company nor NewAmsterdam Pharma presently know or that FLAC, the Company and NewAmsterdam Pharma currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect FLAC’s, the Company’s and NewAmsterdam Pharma’s expectations, plans, or forecasts of future events and views as of the date of this document and are qualified in their entirety by reference to the cautionary statements herein. FLAC, the Company and NewAmsterdam Pharma anticipate that subsequent events and developments will cause FLAC’s, the Company’s and NewAmsterdam Pharma’s assessments to change. These forward-looking statements should not be relied upon as representing FLAC’s, the Company’s and NewAmsterdam Pharma’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither FLAC, the Company, NewAmsterdam Pharma nor any of their respective affiliates undertake any obligation to update these forward-looking statements, except as required by law.
Media Contact
Spectrum Science on behalf of NewAmsterdam Pharma
Carmen Lopez
P: 1 773-306-6285
clopez@spectrumscience.com
Investor Contact
Stern Investor Relations on behalf of NewAmsterdam Pharma
Hannah Deresiewicz
P: 1 212-362-1200
hannah.deresiewicz@sternir.com
